Tag Archives: AACR 2025

Boehringer Ingelheim secures NMPA approval for HERNEXEOS® in HER2-mutant NSCLC with 71% response rate in Beamion-LUNG 1

(IN BRIEF) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has received accelerated approval in China for patients with advanced NSCLC carrying HER2 mutations who have progressed after prior therapy. The approval is supported by Beamion-LUNG 1 data, which showed a 71% objective … Read the full press release